Geode Capital Management Portfolio holdings
Geode Capital Management, founded in 2001 and based in Boston, Massachusetts, is a prominent institutional asset management firm known for its expertise in low-cost, systematic index investing. Originally established to manage internal index funds for Fidelity Investments, Geode became an independent entity while retaining a close relationship with Fidelity, focusing on passive investment strategies that track major market indices. The firm oversees hundreds of billions in assets, offering a range of mutual funds and separately managed accounts primarily for institutional clients, such as pension funds and endowments, with an emphasis on minimizing costs and maximizing efficiency. Geode’s disciplined, quantitative approach and avoidance of active management have made it a key player in the rise of index-based investing.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
S&P Global
SPGI
|
+$216M |
| 2 |
Charter Communications
CHTR
|
+$192M |
| 3 |
SLB Ltd
SLB
|
+$79.3M |
| 4 |
IBM
IBM
|
+$70.2M |
| 5 |
Newell Brands
NWL
|
+$67.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AFFX
Affymetrix Inc
AFFX
|
+$7.53B |
| 2 |
TWC
TIME WARNER CABLE INC NEW COM STK
TWC
|
+$447M |
| 3 |
BXLT
BAXALTA INC COM STK (DE)
BXLT
|
+$229M |
| 4 |
MHFI
MCGRAW-HILL FINANCIAL INC COM
MHFI
|
+$208M |
| 5 |
SANDISK CORP
SNDK
|
+$133M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 14.87% |
| 2 | Technology | 14.38% |
| 3 | Financials | 13.98% |
| 4 | Industrials | 10.32% |
| 5 | Consumer Discretionary | 9.41% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
IMUC
3726
DELISTED
ImmunoCellular Therapeutics, Ltd.
IMUC
| $101K | ﹤0.01% |
10,996
| – | – |
2013 Q2
12 quarters
|
|
3727
Quest Resource Holding
QRHC
$24M
| $100K | ﹤0.01% |
43,175
| – | – |
2014 Q2
8 quarters
|
|
|
GLOWE
3728
DELISTED
GLOWPOINT INC
GLOWE
| $100K | ﹤0.01% |
340,724
| – | – |
2013 Q2
12 quarters
|
|
|
TTF
3729
DELISTED
Thai Fund
TTF
| – | – |
0
| – | – |
2016 Q2
0 quarters
|
|
|
VLTC
3730
DELISTED
Voltari Corporation
VLTC
| $98K | ﹤0.01% |
27,235
| – | – |
2013 Q2
12 quarters
|
|
|
MGN
3731
DELISTED
MINES MGMT INC
MGN
| $98K | ﹤0.01% |
93,274
| – | – |
2013 Q2
12 quarters
|
|
3732
Comstock
LODE
$136M
| $97K | ﹤0.01% |
1,123
| – | – |
2013 Q2
12 quarters
|
|
|
GCH
3733
DELISTED
Aberdeen Greater China Fund
GCH
| – | – |
0
| – | – |
2016 Q2
0 quarters
|
|
|
VRML
3734
DELISTED
Vermillion, Inc.
VRML
| $97K | ﹤0.01% |
88,115
| – | – |
2013 Q2
12 quarters
|
|
3735
INVE Technologies, Inc. Common Stock
INVE
$53.8M
| $96K | ﹤0.01% |
54,157
| – | – |
2013 Q2
12 quarters
|
|
3736
DELISTED
Streamline Health Solutions
STRM
| $95K | ﹤0.01% |
5,315
| – | – |
2013 Q2
12 quarters
|
|
|
QTNT
3737
DELISTED
Quotient Limited Ordinary Shares
QTNT
| $93K | ﹤0.01% |
301
| – | – |
2016 Q1
1 quarter
|
|
|
ONCS
3738
DELISTED
OncoSec Medical Incorporated
ONCS
| $93K | ﹤0.01% |
259
| – | – |
2015 Q3
3 quarters
|
|
|
PTX
3739
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
| $93K | ﹤0.01% |
20,954
-4,358
| -17% | -$28.4K |
2013 Q2
12 quarters
|
|
|
KZ
3740
DELISTED
KongZhong Corporation
KZ
| $92K | ﹤0.01% |
18,260
+3,719
| +26% | +$23K |
2014 Q3
7 quarters
|
|
|
BKEP
3741
DELISTED
Blueknight Energy Partners L.P.
BKEP
| $91K | ﹤0.01% |
17,442
+4,394
| +34% | +$22.4K |
2015 Q1
5 quarters
|
|
3742
Arbutus Biopharma
ABUS
$836M
| $90K | ﹤0.01% |
25,920
+5,717
| +28% | +$24.2K |
2015 Q1
5 quarters
|
|
3743
Virco
VIRC
$102M
| $90K | ﹤0.01% |
20,878
| – | – |
2014 Q3
7 quarters
|
|
|
GMO
3744
DELISTED
General Moly, Inc.
GMO
| $90K | ﹤0.01% |
263,354
| – | – |
2013 Q2
12 quarters
|
|
|
ADYX
3745
DELISTED
Adynxx Inc
ADYX
| $90K | ﹤0.01% |
1,350
| – | – |
2014 Q1
9 quarters
|
|
3746
First US Bancshares
FUSB
$90.7M
| $89K | ﹤0.01% |
10,018
| – | – |
2015 Q4
2 quarters
|
|
3747
NLI Holdings
NL
$324M
| $89K | ﹤0.01% |
34,660
+3,069
| +10% | +$8.75K |
2013 Q2
12 quarters
|
|
3748
Ooma
OOMA
$544M
| $88K | ﹤0.01% |
10,798
| – | – |
2015 Q4
2 quarters
|
|
3749
TCW Strategic Income Fund
TSI
$268M
| – | – |
0
| – | – |
2016 Q1
1 quarter
|
|
|
FOMX
3750
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $88K | ﹤0.01% |
13,929
-24,314
| -64% | -$161K |
2015 Q2
4 quarters
|
|
Similar funds
Geode Capital Management's Q2 2016 Portfolio in Review
As of Q2 2016, Geode Capital Management held 4,187 positions worth $184B, down 2.4% from $188B the previous quarter. Its ten largest holdings account for 15% of the portfolio.
Geode Capital Management withdrew a net $8.49B in Q2 2016, closing 127 positions and reducing 984 holdings. Its most notable exit was Affymetrix Inc, an estimated $7.53B position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 15% of assets, up from 14% a quarter earlier, followed by Technology and Financials.
Against the trend, Geode Capital Management opened a new position in S&P Global worth $215M.
- Geode Capital Management's largest Q2 2016 buy was S&P Global: 2,009,728 shares worth $215M.
- Geode Capital Management added most to Charter Communications in Q2 2016, an estimated $192M increase.
- Geode Capital Management's biggest Q2 2016 reduction was GE Aerospace, cutting an estimated $72.2M.
- Geode Capital Management fully exited Affymetrix Inc in Q2 2016, selling an estimated $7.53B.
- Geode Capital Management's ten largest holdings make up 15% of its $184B portfolio in Q2 2016.
- Geode Capital Management opened 96 new positions and closed 127 in Q2 2016.
- Geode Capital Management's portfolio value fell 2.4% quarter-over-quarter to $184B.
Based on Geode Capital Management's 13F filing for Q2 2016, filed 12 Aug 2016.